About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01434316

Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors

Study identifier: NCT01434316
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Histologically confirmed diagnosis of a solid tumor for which no standard or curative therapy exists or for which standard therapy is no longer effective
  • documented BRCA1 or BRCA2 germline mutation
  • Patients with known active brain metastases are excluded

Type of study:

Phase I study

Treatment:

Patients receive veliparib orally (PO) twice daily (BID) on days 1-28 and dinaciclib IV over 2 hours on days 8 and 22.

Study site:

Massachusetts
Boston
Dana-Farber Cancer Institute
Contact: Geoffrey Shapiro, MD, PhD: 617-632-4942 geoffrey_shapiro@dfci.harvard.edu

 

Page updated 06/08/13

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org